Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$12.15
-2.9%
$8.93
$4.81
$27.50
$406.10MN/A252,439 shs198,240 shs
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$2.90
-2.4%
$4.21
$2.28
$6.71
$367.88M1.851.18 million shs609,283 shs
PureTech Health plc stock logo
PRTC
PureTech Health
$18.20
-4.2%
$17.22
$13.30
$32.98
$437.15M1.144,708 shs1,376 shs
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
$5.24
-1.1%
$4.92
$0.13
$1.04
$100.91M1.581.05 million shs66,805 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
-2.88%+8.87%+35.15%+11.67%+1,214,999,900.00%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
-2.36%-5.84%-34.83%-9.66%+2.84%
PureTech Health plc stock logo
PRTC
PureTech Health
+2.94%+6.31%+6.18%-0.25%-38.31%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-0.56%-3.46%-2.93%-1.12%+2,503.14%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
2.768 of 5 stars
3.50.00.00.02.83.30.6
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
3.9965 of 5 stars
3.31.00.04.33.23.30.6
PureTech Health plc stock logo
PRTC
PureTech Health
2.1186 of 5 stars
3.84.00.00.02.40.00.0
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.50208.64% Upside
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5089.66% Upside
PureTech Health plc stock logo
PRTC
PureTech Health
3.50
Strong Buy$45.00147.25% Upside
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
2.50
Moderate Buy$3.00-42.75% Downside

Current Analyst Ratings Breakdown

Latest VIRI, ORGO, PRTC, and MBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
4/10/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00 ➝ $44.00
4/10/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Outperform$38.00
3/5/2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$4.00 ➝ $6.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$458.76M0.80$0.18 per share15.72$2.11 per share1.37
PureTech Health plc stock logo
PRTC
PureTech Health
$4.32M101.31N/AN/A$16.94 per share1.07
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/A$0.20 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.95M-$0.17N/AN/AN/A-1.62%-2.69%-1.63%N/A
PureTech Health plc stock logo
PRTC
PureTech Health
-$65.70MN/A0.00N/AN/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%8/6/2025 (Estimated)

Latest VIRI, ORGO, PRTC, and MBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
PureTech Health plc stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.21
3.09
2.74
PureTech Health plc stock logo
PRTC
PureTech Health
N/A
3.68
N/A
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
N/A
7.27
7.27

Institutional Ownership

CompanyInstitutional Ownership
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
49.57%
PureTech Health plc stock logo
PRTC
PureTech Health
0.04%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
9.05%

Insider Ownership

CompanyInsider Ownership
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
36.90%
PureTech Health plc stock logo
PRTC
PureTech Health
5.30%
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.42 millionN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
950126.85 million79.33 millionOptionable
PureTech Health plc stock logo
PRTC
PureTech Health
10024.02 million22.67 millionNot Optionable
Virios Therapeutics, Inc. stock logo
VIRI
Virios Therapeutics
519.26 million16.91 millionOptionable

Recent News About These Companies

Dogwood Therapeutics Inc (DWTX)
Dogwood prices 578,950 shares at $8.26 in registered direct offering
Dogwood announces conversion of existing $19.5M in debt to equity
DWTX Stock trading resumes
Dogwood Therapeutics, Inc. (DWTX)
DWTX Stock trading halted, volatility trading pause
Dogwood announces first patient dosed in Phase 2b trial on Halneuron
Dogwood Therapeutics faces potential Nasdaq delisting
Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue
Dogwood Therapeutics Reports Q3 2024 Financial Results
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$12.15 -0.36 (-2.88%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$12.15 0.00 (0.00%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.90 -0.07 (-2.36%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.95 +0.05 (+1.72%)
As of 05/23/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$18.20 -0.80 (-4.21%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$18.08 -0.13 (-0.69%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Virios Therapeutics stock logo

Virios Therapeutics NASDAQ:VIRI

$5.24 -0.06 (-1.13%)
As of 05/23/2025

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.